Development and Applications of Asymmetric Hydrovinylation of Alkenes

烯烃不对称氢乙烯基化的研究进展及应用

基本信息

  • 批准号:
    7623571
  • 负责人:
  • 金额:
    $ 23.6万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2007
  • 资助国家:
    美国
  • 起止时间:
    2007-08-01 至 2010-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): By every measure the demand for enantiomerically pure intermediates for the synthesis of chiral pharmaceutical products keeps mounting. Discovery of new asymmetric reactions, especially those which would yield practical levels of asymmetric induction and high turnover frequencies (i.e., substrate/catalyst/unit time), will have significant impact on medicinal as well as process chemistry. Through an approach that relies primarily on mechanistic insights and systematic examination of ligand effects, we have discovered a number of protocols for the enantioselective heterodimerization reactions of ethylene with vinylarenes, 1,3-dienes and strained olefins. We have also uncovered reactions for the asymmetric generation of all-carbon quaternary centers, which are otherwise difficult to install. Mild reaction conditions, tolerance to various functional groups, isolated yields >95%, substrate/catalyst ratios of 100-1000 and enantioselectivities of 90-99% ee for various reaction imply that hydrovinylation could be developed into a practical process for the synthesis of molecules with a chiral 3-(alkyl or aryl)-1-butene motif. Many biologically important molecules can be easily accessed from these intermediates. Examples illustrated include powerful anti-inflammatory, antitumor and antituberculosis agents. In some cases these are the first enantioselective syntheses, while in others, where analog synthesis could benefit clinical studies, the relative merits of this approach vis-a-vis known methods are pointed out. Broadly, the goals of this project are two fold: (a) Improvements in the selectivity and scope of hydrovinylation. Following our preliminary results, we want to explore and expand the scope, and applications of the hydrovinylation of vinyl arenes, 1,3-dienes and strained olefins, including those give chiral all-carbon quaternary centers. This would involve the discovery of new protocols, and of new chiral ligands for this exacting reaction, (b) Application of asymmetric hydrovinylation in total synthesis of natural products. A general solution to the classical problem of installation of exocyclic chiral centers will be illustrated with synthesis of (-)-laurenditerpenol, steroid C/D ring analogs, helioporins and pseudopterosins and serotonin antagonist LY426965. Stereoselective syntheses of these compounds are especially important because of their varied biological activities (including cytotoxic, anti-inflammatory and antimycobacterial properties), dependence of such activities on the configuration of each of the chiral centers, and paucity of methods for absolute stereochemical control in C-C bond formations. Hydrovinylation offers outstanding opportunities in this regard. Applications aside, we hope that the study of the reaction would reveal new control elements useful for the development of new, broadly applicable, tools for catalytic asymmetric synthesis.
描述(由申请人提供):通过各种衡量标准,对用于合成手性药物产品的对映体纯中间体的需求不断增加。发现新的不对称反应,特别是那些将产生实际水平的不对称诱导和高转换频率的反应(即,底物/催化剂/单位时间)的变化将对药物以及工艺化学产生显著影响。通过一种方法,主要依赖于机械的见解和系统的检查配体的影响,我们已经发现了一些协议的乙烯与乙烯基芳烃,1,3-二烯和应变烯烃的对映选择性异二聚反应。我们还发现了不对称生成全碳季中心的反应,否则很难安装。温和的反应条件、对各种官能团的耐受性、> 95%的分离产率、100-1000的底物/催化剂比和90- 99%ee的各种反应的对映选择性意味着加氢乙烯化可以发展成为合成具有手性3-(烷基或芳基)-1-丁烯基序的分子的实用方法。许多生物学上重要的分子可以很容易地从这些中间体中获得。举例说明的例子包括强大的抗炎,抗肿瘤和抗结核药物。在某些情况下,这些是第一个对映体选择性合成,而在其他情况下,类似物的合成可能有利于临床研究,这种方法相对维斯已知的方法的相对优点被指出。概括地说,该项目的目标有两个方面:(a)提高加氢乙烯化的选择性和范围。根据我们的初步结果,我们希望探索和扩大乙烯基芳烃,1,3-二烯和应变烯烃的加氢乙烯化的范围和应用,包括那些产生手性全碳季中心的加氢乙烯化。这将涉及发现新的方案和用于该严格反应的新的手性配体。(B)不对称氢化乙烯基化在天然产物的全合成中的应用。环外手性中心的安装的经典问题的一般解决方案将说明与合成(-)-劳伦二萜醇,类固醇C/D环类似物,helioporins和pseudopterosins和5-羟色胺拮抗剂LY 426965。这些化合物的立体选择性合成是特别重要的,因为它们的不同的生物活性(包括细胞毒性,抗炎和抗分枝杆菌的性能),这些活动的依赖于每个手性中心的构型,和缺乏的方法,绝对立体化学控制在C-C键的形成。氢乙烯化在这方面提供了绝佳的机会。除了应用程序,我们希望该反应的研究将揭示新的控制元素,用于开发新的,广泛适用的,催化不对称合成的工具。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

T V RAJANBABU其他文献

T V RAJANBABU的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('T V RAJANBABU', 18)}}的其他基金

Highly Selective Catalytic Reactions of Alkenes and Alkynes Relevant to Medicinal and Process Chemistry
与医药和工艺化学相关的烯烃和炔烃的高选择性催化反应
  • 批准号:
    10544730
  • 财政年份:
    2021
  • 资助金额:
    $ 23.6万
  • 项目类别:
Highly Selective Catalytic Reactions of Alkenes and Alkynes Relevant to Medicinal and Process Chemistry
与医药和工艺化学相关的烯烃和炔烃的高选择性催化反应
  • 批准号:
    10320911
  • 财政年份:
    2021
  • 资助金额:
    $ 23.6万
  • 项目类别:
Highly Selective Catalytic Reactions of Alkenes and Alkynes Relevant to Medicinal and Process Chemistry
与医药和工艺化学相关的烯烃和炔烃的高选择性催化反应
  • 批准号:
    10581995
  • 财政年份:
    2021
  • 资助金额:
    $ 23.6万
  • 项目类别:
New Alkene Chemistry for the Synthesis of Medicinally Relevant Compounds
用于合成医学相关化合物的新烯烃化学
  • 批准号:
    9297349
  • 财政年份:
    2015
  • 资助金额:
    $ 23.6万
  • 项目类别:
Development and Applications of Asymmetric Hydrovinylation of Alkenes
烯烃不对称氢乙烯基化的研究进展及应用
  • 批准号:
    7858243
  • 财政年份:
    2007
  • 资助金额:
    $ 23.6万
  • 项目类别:
Development and Applications of Asymmetric Hydrovinylation of Alkenes
烯烃不对称氢乙烯基化的研究进展及应用
  • 批准号:
    7473969
  • 财政年份:
    2007
  • 资助金额:
    $ 23.6万
  • 项目类别:
Development and Applications of Asymmetric Hydrovinylation of Alkenes
烯烃不对称氢乙烯基化的研究进展及应用
  • 批准号:
    7320569
  • 财政年份:
    2007
  • 资助金额:
    $ 23.6万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 23.6万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.6万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 23.6万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.6万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 23.6万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 23.6万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.6万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 23.6万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 23.6万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.6万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了